Karyopharm stock slumped 13% pre-market despite its myelofibrosis treatment meeting a primary Phase 3 endpoint. Investors expressed doubt over FDA approval due to a lack of meaningful improvement in secondary endpoints. The company also announced a $30 million private placement with RA Capital Management.